This site is intended for U.S. healthcare professionals.
An oral treatment combination for adults with unresectable or metastatic melanoma with a BRAF V600E/K mutation1,2
Time to response was not a prespecified endpoint. These data are presented for descriptive purposes only.
Time to response was the time between the date of randomization until first documented response of CR or PR
At time of primary analysis (data cutoff: May 19, 2016), the median time to response by BICR in responding patients was 1.8 months (95% CI: 1.8-1.9) for the BRAFTOVI + MEKTOVI group and 1.9 months (95% CI: 1.8-1.9) for the vemurafenib group
Median time to response data only represent patients who responded to therapy. Please refer to the previous page for overall response rates among patients taking BRAFTOVI + MEKTOVI.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) are kinase inhibitors indicated for use in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.